Table 3.
Analyses of prognostic factors for progression free survival
| Variables | Two‐year PFS rate (%) | P | |
|---|---|---|---|
| Univariate | Multivariate | ||
| Age (years) | |||
| ≤60 vs. >60 | 14.0 vs. 69.1 | 0.059 | 0.082 |
| Gender | |||
| Male vs. Female | 51.5 vs. 53.3 | 0.710 | 0.914 |
| Histology | |||
| AD vs. SqCC + other | 54.2 vs. 48.9 | 0.598 | 0.489 |
| Stage | |||
| I vs. II/IIIA | 58.4 vs. 40.4 | 0.355 | 0.792 |
| Recurrence interval | |||
| <12 vs. ≥12 months | 33.3 vs. 60.7 | 0.117 | 0.128 |
| Recurrent LN site | |||
| Station 2, 3, 5, 6, and SCLN vs. others | 42.2 vs. 54.9 | 0.379 | 0.294 |
| Recurrent LN number | |||
| Single vs. multiple | 51.4 vs. 49.7 | 0.502 | 0.676 |
| Recurrent LN size | |||
| <3 cm vs. ≥3 cm | 62.3 vs. 14.6 | 0.013 | 0.030 |
| Total dose (BED, Gy10) | |||
| ≤75 vs. >75 | 27.8 vs. 56.8 | 0.318 | 0.889 |
| Chemotherapy | |||
| RT + CTx vs. RT alone | 61.7 vs. 38.7 | 0.352 | 0.730 |
Bold text signifies P < 0.05. AD, adenocarcinoma; BED, biologically equivalent dose; CTx, chemotherapy; LN, lymph node; PFS, progression‐free survival; RT, radiotherapy; SCLN, supraclavicular lymph node; SqCC, squamous cell carcinoma.